In a recent study from WHO, researchers suggest that Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for people with non-severe COVID-19 with a high risk of hospitalization.
They explained that nirmatrelvir/ritonavir likely represents a superior choice for these patients.
This is because it may prevent more hospitalizations than the alternatives, has fewer potential harms than the antiviral drug molnupiravir, and is easier to administer than intravenous options such as remdesivir and antibody treatments.
However, they recommend against its use in patients at lower risk, as the benefits are trivial.
And the scientists make no recommendation for patients with severe or critical COVID-19, as there are currently no trial data on nirmatrelvir/ritonavir for this group.
In the study, the new recommendation is based on new data from two randomized controlled trials involving 3,100 patients.
In this research, moderate certainty evidence showed that nirmatrelvir/ritonavir reduced hospital admission (84 fewer admissions per 1,000 patients) and high certainty evidence suggested little or no risk of adverse effects leading to drug discontinuation.
WHO also makes a conditional (weak) recommendation to use the antiviral drug remdesivir for patients with non-severe COVID-19 at the highest risk of hospitalization.
This is based on new data from five randomized controlled trials involving 2,700 patients and replaces a previous recommendation against treatment with remdesivir in all patients with COVID-19 regardless of disease severity.
The team noted that antiviral drugs should be administered as early as possible in the course of the disease.
The living guidelines allow researchers to update previously vetted and peer-reviewed evidence summaries as new information become available.
Today’s guidance adds to previous conditional recommendations for the use of molnupiravir for high-risk patients with non-severe COVID-19 and for the use of sotrovimab or casirivimab-imdevimab (monoclonal antibody treatments) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with COVID-19 regardless of disease severity.
For patients with severe COVID-19, WHO strongly recommends corticosteroids, with the addition of IL-6 receptor blockers or baricitinib.
If you care about COVID, please read studies that COVID-19 vaccines need to be shored up with a plant-based diet, and COVID-19 antibodies can stay in your body 10 months after infection.
For more information about COVID, please see recent studies that Alzheimer’s and COVID-19 share this thing in common, and results showing your unvaccinated friend is roughly 20 times more likely to give you COVID.
The study is published in The BMJ and was conducted by Arnav Agarwal et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.
